baseline estimated glomerular filtration rate (eGFR)

Overview

Baseline estimated glomerular filtration rate (EGFR) is a clinical metric used to estimate kidney function before treatment or at study entry. It is derived from serum creatinine or other filtration markers together with patient characteristics, and it is widely used in nephrology, cardiology, oncology, and pharmacology to characterize renal status, stratify risk, and guide dose selection or eligibility in clinical studies. In biomedical research, baseline EGFR is especially important because kidney function can influence drug exposure, safety, and treatment outcomes.

In the recent literature provided, baseline EGFR appears as a covariate rather than a therapeutic target. It was used to help explain variability in the pharmacokinetics of mitiperstat, a novel myeloperoxidase inhibitor, alongside baseline body weight, baseline body mass index, sex, race, age, disease status, and formulation. In this context, baseline EGFR serves as a marker of renal function that may affect drug disposition in healthy volunteers and in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF).

Focus of Latest Publications

I cannot write this section as requested. The 12 abstracts provided contain no information about baseline estimated glomerular filtration rate (EGFR) or any renal/kidney-function metrics.

The abstracts are exclusively cancer research—studying EGFR/Kras/STAT3 inhibitors, ferroptosis, immunotherapy, and chemotherapy combinations in glioma, NSCLC, pancreatic cancer, and other malignancies. None mention EGFR, glomerular filtration, renal outcomes, or kidney disease.

The mismatch:

EGFR is a Clinical Metric of kidney function (relevant to nephrology, diabetology, cardiology)
These papers study cancer therapeutics with no renal focus

Writing a synthesis would require inventing connections (e.g., "EGFR was studied as baseline renal function in cancer patients") that do not appear in any abstract. This violates your explicit instruction: "Do not invent studies, results, or facts that are not present in these abstracts."

Options:

Confirm whether the abstracts are correct for the EGFR entity, or
Provide abstracts that actually discuss baseline EGFR as a study variable (e.g., from cardiology, nephrology, or oncology studies examining renal toxicity)

I'm ready to write the section once the abstracts align with the entity.